Leitlinie
NCCN Guideline Updates on Radiopharmaceutical Therapy for Prostate Cancer
European Urology Focus · 2026-10 · 12 (5) · 877-879
DOI: 10.1016/j.euf.2026.05.005 ↗Kurz gefasst
Leitlinie in der Zeitschrift European Urology Focus, 2026-10. Verfasst von Praful Ravi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA, USA. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Boston, MA, USA.
- City of Hope, Duarte, CA, USA.
- Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: aliciak_morgans@dfci.harvard.edu.
Zitieren
APA
Ravi, P., Dorff, T. B., & Morgans, A. K. (2026). NCCN Guideline Updates on Radiopharmaceutical Therapy for Prostate Cancer. European Urology Focus, 12(5), 877-879. https://doi.org/10.1016/j.euf.2026.05.005
Vancouver
Ravi P, Dorff TB, Morgans AK. NCCN Guideline Updates on Radiopharmaceutical Therapy for Prostate Cancer. European Urology Focus. 2026;12(5):877-879. doi:10.1016/j.euf.2026.05.005
BibTeX
@article{Ravi2026,
author = {Ravi, Praful and Dorff, Tanya Barauskas and Morgans, Alicia K},
title = {NCCN Guideline Updates on Radiopharmaceutical Therapy for Prostate Cancer},
journal = {European Urology Focus},
year = {2026},
volume = {12},
number = {5},
pages = {877--879},
doi = {10.1016/j.euf.2026.05.005}
}
EUVIMED